DNDN
DNDN Articles
The short interest data is out using the June 15 settlement date and we have compared this to the May 31 settlement date and prior periods for a comparison. With choppy markets in June after a...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Tuesday. Ace Ltd. (NYSE: ACE) Started as Buy at Stern Agee. American...
Published:
Last Updated:
Jon OggThe short interest data is out using the May 31 settlement date. As the market dropped so much in May, it is an interesting look to see what short sellers did in the active cult and widely...
Published:
Last Updated:
We have several shares of biotech stocks on the move, but frankly the news from th American Society of Clinical Oncology, or ASCO, looks a bit muted. So far these are the winners and losers in the...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Wednesday. Applied Materials Inc. (NASDAQ: AMAT) Raised to Neutral at Goldman...
Published:
Last Updated:
The three major US stock indexes opened somewhat higher this morning as investors paid little attention to last night’s downgrade of Spain’s banks (more coverage here). With little economic data...
Published:
Last Updated:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Friday. Angie’s List, Inc. (NASDAQ: ANGI) Started as Outperform at Raymond...
Published:
Last Updated:
We are now just about two weeks away from the king of biotech and pharma events in cancer treatments. The 2012 annual meeting of the American Society of Clinical Oncology (ASCO) is set to take...
Published:
Last Updated:
The three major US stock indexes opened essentially flat this morning as investors were faced with a flat report on new claims for jobless benefits (our coverage here). Manufacturing data from the...
Published:
Last Updated:
AuthorDendreon Corporation (NASDAQ: DNDN) is in trouble. That is what the performance is telling investors. The maker of Provenge as a late-stage prostate cancer treatment has three issues...
Published:
Last Updated:
It is now getting close to the middle of May, and that means one thing for biotech investors. The king of biotech and pharma events is about to take place. The 2012 annual meeting of the American...
Published:
Last Updated:
Jon OggThe short interest data is out using the April 30 settlement date. We have seen some drastic changes from the April 13 settlement date in many issues, followed by some surprises where the...
Published:
Last Updated:
The major US stock indexes opened sharply lower this morning as weak performance in the European markets as traders try to figure out what last weekend’s elections mean. Crude oil was also sharply...
Published:
Last Updated:
When we issued our earnings previews for the week ahead, it looked as though Dendreon Corporation (NASDAQ: DNDN) had a chance of really setting the trend for the entire biotech sector this week. ...
Published:
Last Updated:
AuthorDendreon Corporation (NASDAQ: DNDN) has reported its quarterly results and the reaction is a bit cool. This is growth of almost 200%, as net product revenue for the quarter was $82.0 million...
Published:
Last Updated: